OUR MUlti-target

Pipeline

We have accelerated our lead 1st-in-class compound from early discovery to Phase 2 in 2.5 years with seed capital. Using our “Platform-in-a-Mechanism” model, we have built a pipeline across 2 different targets for 3 therapeutic areas. We plan to accelerate 2 additional indications to IND in next 12 months using our super-efficiency model.
Asset 1
GEn-1124 IV
p38α:MK2 Dual Signal Modulator
Area
Respiratory
Disease
ARDS (w/BARDA)
Pipeline-in-a-Product
Discovery
Lead Op
Pre-Clinical
IND-Enabled
Ph 1
Ph 2
Ph 3
ARDS (w/BARDA)
Pipeline-in-a-Product
Asset 2
Chronic Oral
p38α:MK2 Dual Signal Modulator
Area
Stealth
Disease
Stealth
Discovery
Lead Op
Pre-Clinical
IND-Enabled
Ph 1
Ph 2
Ph 3
Asset 3
Chronic Oral
‍NextGen ERK 1/2
Area
Immuno-oncology
Disease
Stealth
Discovery
Lead Op
Pre-Clinical
IND-Enabled
Ph 1
Ph 2
Ph 3

IV

p38α:MK2 Dual Signal Modulator
ARDS
GEn-1124
Learn more

Chronic Oral

p38α:MK2 Dual Signal Modulator
Stealth
🔒 Learn more

Chronic Oral

NextGen ERK 1/2
Stealth
🔒 Learn more
Main pages
HomePipelineDifferentiationAI PlatformPartnersAboutMediaContact usPolicies
© GEn1E Lifesciences Inc.

This website stores cookies on your computer and we use the cookies to optimize your user experience and allow us to improve our website. By continuing to use our site, clicking "Accept Cookies", or closing this banner, you agree to the terms of our Website Privacy Policy.
CALIFORNIA RESIDENTS: If you would like to exercise any of your consumer privacy rights under the California Consumer Privacy Act (“CCPA”), please click here to access the CCPA Privacy Policy.

Accept Cookies